Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Key facts

Sponsor

Memorial Sloan Kettering Cancer Center

Principal Investigator

Thomas Kaley, MD

Memorial Sloan Kettering Cancer Center

Intervention

Pembrolizumab(drug)

Enrollment

27 target

Eligibility

18 years · All sexes

Timeline

2016 – 2027

Study locations (16)

• University of California, Los Angeles, Los Angeles, California, United States
• University of California San Francisco, San Francisco, California, United States
• University of Miami, Miami, Florida, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Brigham and Women's Hospital, Boston, Massachusetts, United States
• Dana Farber Cancer Institute, Boston, Massachusetts, United States
• Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
• Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
• Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
• Memorial Sloan Kettering Commack, Commack, New York, United States
• Memorial Sloan Kettering Westchester, Harrison, New York, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Memorial Sloan Kettering Nassau, Uniondale, New York, United States
• Cleveland Clinic, Cleveland, Ohio, United States
• Md Anderson Cancer Center, Houston, Texas, United States
• +1 more locations on ClinicalTrials.gov

Collaborators

Merck Sharp & Dohme LLC · M.D. Anderson Cancer Center · Dana-Farber Cancer Institute · University of California, San Francisco · Huntsman Cancer Institute/ University of Utah · University of California, Los Angeles · University of Miami

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Embryonal tumor of neuroepithelial tissue

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07488754
  Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
  Medical University of Warsaw
• RECRUITINGPHASE1NCT07025018
  Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
  Hutchmed
• RECRUITINGNANCT06719440
  Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume
  Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• RECRUITINGPHASE2NCT06558214
  OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
  University of Florida
• RECRUITINGPHASE3NCT06496971
  A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
  NaviFUS Corporation
• RECRUITINGPHASE2NCT07364786
  Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
  Peter Siesjö
• RECRUITINGEARLY PHASE1NCT06828341
  A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
  JIANG LONGWEI
• RECRUITINGPHASE2NCT05708352
  A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
  Cedars-Sinai Medical Center

See all trials for Embryonal tumor of neuroepithelial tissue →